Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

GlobeNewswire 42 minutes ago

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

GlobeNewswire October 31, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

GlobeNewswire October 17, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

GlobeNewswire September 3, 2024

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

GlobeNewswire August 6, 2024

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

GlobeNewswire August 1, 2024

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

GlobeNewswire July 30, 2024

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

GlobeNewswire July 28, 2024

Lifshitz Law PLLC Announces Investigations of Palo Alto Networks, Inc. (NASDAQ: PANW), Lyft, Inc. (NASDAQ: LYFT), Anavex Life Sciences Corporation (NASDAQ: AVXL), and GrafTech International Ltd. (NYSE: EAF)

Accesswire June 25, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire June 20, 2024

Anavex Life Sciences Announces Expansion of Leadership Team

GlobeNewswire May 22, 2024

Lifshitz Law PLLC Announces Investigations of Anavex Life Sciences Corporation (NASDAQ:AVXL), Innoviz Technologies Ltd. (NASDAQ:INVZ), agilon health, inc. (NYSE:AGL), and The Chemours Company (NYSE:CC)

Accesswire May 21, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

GlobeNewswire May 14, 2024

Anavex Life Sciences Corporation Class Action: Levi & Korsinsky Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL

Accesswire May 13, 2024

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm

Accesswire May 13, 2024

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class Action - AVXL

Accesswire May 13, 2024

Faruqi & Faruqi, LLP Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024

Newsfile May 13, 2024

Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire May 13, 2024

AVXL LAWSUIT ALERT: Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire May 13, 2024

Investors who lost money on Anavex Life Sciences Corporation (AVXL) should contact Levi & Korsinsky about pending Class Action - AVXL

Accesswire May 13, 2024